Article
Gilead's Dan O'Day pulls the plug on the lion's share of their filgotinib collaboration as th
Rating:
0.0
Views:
116
Likes:
1
Library:
1
Five years after Gilead plunked down $725 million in cash to partner with Galapagos on filgotinib, new CEO Dan O'Day has opted to shelve the rheumatoid arthritis program and all but a much smaller piece of the old development plan in the US. The big biotech said Tuesday afternoon that
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value